Study Update Shows Tremelimumab Unlikely to Improve Mesothelioma...

Investigators now say the monoclonal antibody does not appear to work as a second- or third-line treatment option for mesothelioma patients.(PRWeb July 25, 2017)Read the full story at http://www.prweb.com/releases/2017/07/prweb14534100.htm
Source: PRWeb: Medical Pharmaceuticals - Category: Pharmaceuticals Source Type: news